ACOR - Acorda Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.02
-0.51 (-4.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.53
Open11.32
Bid11.04 x 2200
Ask11.05 x 3200
Day's Range10.97 - 11.71
52 Week Range9.58 - 36.35
Volume789,782
Avg. Volume879,060
Market Cap530.389M
Beta (3Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-0.12
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.25
Trade prices are not sourced from all markets
  • Is Acorda Therapeutics Inc (ACOR) A Good Stock To Buy?
    Insider Monkey10 days ago

    Is Acorda Therapeutics Inc (ACOR) A Good Stock To Buy?

    Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter. NASDAQ and Russell 2000 indices were already in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by nearly 7 percentage points in the fourth quarter. Hedge funds and institutional […]

  • Markit12 days ago

    See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

    Acorda Therapeutics Inc NASDAQ/NGS:ACORView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderately high for ACOR with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ACOR are favorable, with net inflows of $3.56 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEvents13 days ago

    Edited Transcript of ACOR earnings conference call or presentation 2-May-19 12:30pm GMT

    Q1 2019 Acorda Therapeutics Inc Earnings Call

  • Acorda Therapeutics (ACOR) Q1 2019 Earnings Call Transcript
    Motley Fool15 days ago

    Acorda Therapeutics (ACOR) Q1 2019 Earnings Call Transcript

    ACOR earnings call for the period ending March 31, 2019.

  • Acorda (ACOR) Earnings and Revenues Beat Estimates in Q1
    Zacks17 days ago

    Acorda (ACOR) Earnings and Revenues Beat Estimates in Q1

    Acorda's (ACOR) shares rise on earnings and revenue beat in Q1. Inbrija registers first sales figure following its launch in the reported quarter.

  • Benzinga17 days ago

    The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 1) Alcon AG (NYSE: ALC ) (announced presentation of new ...

  • Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates
    Zacks17 days ago

    Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates

    Acorda (ACOR) delivered earnings and revenue surprises of 42.27% and 20.49%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press17 days ago

    Acorda: 1Q Earnings Snapshot

    The Ardsley, New York-based company said it had a loss of $1 per share. Losses, adjusted for non-recurring costs and stock option expense, came to 56 cents per share. The results topped Wall Street expectations. ...

  • Business Wire17 days ago

    Acorda Provides Update for First Quarter Ended March 31, 2019

    ARDSLEY, N.Y.-- -- INBRIJA™ commercially available on February 28; first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in people with Parkinson’s taking carbidopa/levodopa INBRIJA 1Q 2019 net sales of $1.3 million; approximately 2,000 prescription request forms received through April 2019 AMPYRA ® 1Q 2019 net sales of $40.1 million Acorda Therapeutics, Inc. provided ...

  • Earnings Preview: Acorda Therapeutics (ACOR) Q1 Earnings Expected to Decline
    Zacks24 days ago

    Earnings Preview: Acorda Therapeutics (ACOR) Q1 Earnings Expected to Decline

    Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Should You Be Concerned About Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Historical Volatility?
    Simply Wall St.27 days ago

    Should You Be Concerned About Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Historical Volatility?

    If you're interested in Acorda Therapeutics, Inc. (NASDAQ:ACOR), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. Volatility is conside...

  • Business Wirelast month

    Acorda First Quarter 2019 Update: Webcast/Conference Call Scheduled for May 2, 2019

    Acorda Therapeutics, Inc. (ACOR) will host a conference call and webcast to report its first quarter 2019 update and financial results on Thursday, May 2 at 8:30 a.m. ET. The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.

  • Acorda to Gain From Inbrija Sales and Neurological Pipeline
    Zackslast month

    Acorda to Gain From Inbrija Sales and Neurological Pipeline

    Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.

  • Business Wire2 months ago

    Acorda to Present New Long-Term Data for INBRIJA™ (levodopa inhalation powder) at Academy of Managed Care Pharmacy Annual Meeting

    Acorda Therapeutics, Inc. (ACOR) will present three posters with Phase 3 data on INBRIJA at the upcoming Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting taking place March 25-28, 2019, in San Diego. INBRIJA was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2018 for intermittent treatment of OFF episodes in people with Parkinson’s taking carbidopa/levodopa.

  • Acorda (ACOR) Down 6% Since Last Earnings Report: Can It Rebound?
    Zacks2 months ago

    Acorda (ACOR) Down 6% Since Last Earnings Report: Can It Rebound?

    Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Acorda Therapeutics (ACOR) Gains But Lags Market: What You Should Know
    Zacks2 months ago

    Acorda Therapeutics (ACOR) Gains But Lags Market: What You Should Know

    In the latest trading session, Acorda Therapeutics (ACOR) closed at $14.62, marking a +0.14% move from the previous day.

  • Should You Be Concerned About Acorda Therapeutics, Inc.’s (NASDAQ:ACOR) ROE?
    Simply Wall St.2 months ago

    Should You Be Concerned About Acorda Therapeutics, Inc.’s (NASDAQ:ACOR) ROE?

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use ReturnRead More...

  • Business Wire2 months ago

    Acorda Therapeutics Announces Management Changes

    Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Andrew Hindman, Chief Business Officer, will transition out of the Company over the coming months. “We thank Andrew for his many contributions to Acorda over the past five years. One of his first achievements was helping to lead Acorda’s acquisition of Civitas and INBRIJA, which was transformational for the Company,” said Ron Cohen, M.D., Acorda’s President and CEO.

  • Business Wire2 months ago

    Acorda to Present at Oppenheimer’s 29th Annual Healthcare Conference

    Acorda Therapeutics, Inc. (ACOR) announced that Andrew Hindman, Acorda’s Chief Business Officer, will present at the Oppenheimer & Co. Annual Healthcare Conference on Tuesday, March 19 at 1:35 p.m. EST. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA™ (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa.

  • GlobeNewswire2 months ago

    Glancy Prongay & Murray LLP Announces Investigation on Behalf of Acorda Therapeutics, Inc. Investors (ACOR)

    LOS ANGELES, March 05, 2019 -- Glancy Prongay & Murray LLP (“GPM”) announces its investigation on behalf of Acorda Therapeutics, Inc. (NASDAQ: ACOR) investors concerning.

  • GlobeNewswire2 months ago

    Detailed Research: Economic Perspectives on Huntsman, eHealth, Ionis Pharmaceuticals, Arch Capital Group, Copart, and Acorda Therapeutics — What Drives Growth in Today's Competitive Landscape

    NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire3 months ago

    Acorda Therapeutics Announces Commercial Launch of INBRIJA™ (levodopa inhalation powder)

    Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that INBRIJA is now available by prescription in the United States. INBRIJA was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2018 for intermittent treatment in people with Parkinson’s taking carbidopa/levodopa who experience OFF episodes. “OFF periods are extremely disruptive for those living with Parkinson’s. We are excited that INBRIJA is now available to address this important unmet medical need, and that prescriptions are already being filled,” said Ron Cohen, M.D., Acorda’s President and CEO.